Dose: 0.002 to 0.008 mg/kg
Single Dose: 0.005 (0.005)
Frequency: As recommended.
Route: PO
Instructions: As required

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

belongs to Methylpyrimidine. It belongs to Alpha-2 adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Antihypertensive Agents pharmacological group.The Molecular Weight of Moxonidine is 241.70.

'Moxonidine is contraindicated in conditions like Depression,Glucoma,Parkinsonism,Raynaud''s phenomenon.'

The symptomatic adverse reactions produced by Moxonidine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Tiredness, Headache, Anorexia, Constipation, Sleep disturbancesX, Dry mouth, Itching, Burning, Dry mouth, dizziness.

Moxonidine is primarily indicated in conditions like Hypertension, Mild iron-deficiency anaemias.

Moxonidine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAldesleukinEnhanced hypotensive effect when aldesleukin given with Moxonidine.AlprostadilEnhanced hypotensive effects when alprostadil given with Moxonidine.DiazoxideEnhanced hypootensive effect when Diazoxide given with Moxonidine.HydrochlorothiazideConcomitant administration of moxonidine and hydrochlorothiazide is not indicated, as hypotensive effect of both drugs may be enhanced. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store in a well closed container.

Moxonidine should not be given to patients with conduction disorder, bradycardia, severe arrhythmias, severe heart failure, severe ischaemic heart disease, severe liver or kidney impairment or history of angioedema. It should not be stopped abruptly but should be withdrawn gradually over 2 weeks.